Search press releases
Every release here is real and links to its original. Filter by company, topic, language and date.
- Pfizer Inc.Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental VitiligoCompanies: PfizerNEW YORK, October 02, 2026--Pfizer Inc. (NYSE: PFE) today presented results from two Phase 3 trials evaluating the efficacy and safety of LITFULO® (ritlecitinib) as a once-daily oral treatment across a wide range of disease extent.
- Global Cyclic Peptide Library Market Outlook and Forecast, 2026-2032 - AI-Enabled Discovery Fuels 16.32% CAGR Toward USD 9.86 Billion as PeptiDream, Bicycle Therapeutics, Pfizer and Roche Advance CompetitionCompanies: PfizerRoche HoldingBoost ROI with question-led libraries, reproducible synthesis, validated assays, interoperable data, AI feedback loops, partnerships, and early planning for IP, regulation, supply and talent
- Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 VaccineCompanies: PfizerPfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies’ 2026-2027 COVID-19 vaccine formula targeting the XFG variant (COMIRNATY® XFG; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.1
- Pfizer Inc.Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 VaccineCompanies: PfizerNEW YORK & MAINZ, Germany, August 27, 2026--Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies’ 2026-2027 COVID-19 vaccine formula targeting the XFG variant (COMIRNATY® XFG; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying cond